Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases.
about
Brain immune interactions and air pollution: macrophage inhibitory factor (MIF), prion cellular protein (PrP(C)), Interleukin-6 (IL-6), interleukin 1 receptor antagonist (IL-1Ra), and interleukin-2 (IL-2) in cerebrospinal fluid and MIF in serum diffGene therapy prolongs survival and restores function in murine and canine models of myotubular myopathy.Cerebrospinal fluid ceramides from patients with multiple sclerosis impair neuronal bioenergetics.Fatigue in patients with multiple sclerosis: is it related to pro- and anti-inflammatory cytokines?Monocyte and microglial activation in patients with mood-stabilized bipolar disorder.Multiplex assessment of a panel of 16 serum molecules for the differential diagnosis of Alzheimer's diseaseThe effectiveness of aerobic training, cognitive behavioural therapy, and energy conservation management in treating MS-related fatigue: the design of the TREFAMS-ACE programmeAntisense oligonucleotide inhibition of cholesteryl ester transfer protein enhances RCT in hyperlipidemic, CETP transgenic, LDLr-/- miceA sensitive and specific quantitation method for determination of serum cardiac myosin binding protein-C by electrochemiluminescence immunoassay.Opportunities for bead-based multiplex assays in veterinary diagnostic laboratories.Detection of anti-cytokine antibodies and their clinical relevance.An update on the use of cerebrospinal fluid analysis as a diagnostic tool in multiple sclerosis.Quantification of cytokines secreted by primary human cells using multiple reaction monitoring: evaluation of analytical parameters.Maternal serum cytokines at 30-33 weeks in the prediction of preeclampsia.Coffee consumption modulates inflammatory processes in an individual fashion.Analysis of inflammatory cytokines in human blood, breath condensate, and urine using a multiplex immunoassay platform.
P2860
Q30416813-8BB5A776-9706-4497-A65E-011904BDA10BQ33926944-A97FDA2A-3CA8-436F-8B4C-6EEAE90D9267Q34422726-13AE18D3-54CB-4443-8F04-11039F3F10C1Q35036908-C1680A1E-F766-4869-9557-55B1A9A78AF3Q35772084-ED380ACC-A59D-4BB4-A10D-0855300F793BQ36695912-66607687-87C8-4A6E-B97B-1003817472EBQ37116754-9B8621D9-EAA9-4477-A6AE-CC340720229FQ37163010-007387FD-F6AF-4F60-92FB-ABEBA6D25CC0Q37372200-13B9E50E-EFEE-4E92-9961-2DA3DB855D31Q38155042-BB918DE5-53AC-439F-8228-A76F3A12B442Q38217701-722FE177-CB30-4567-AEB8-A019A5D760E6Q39027028-175FFAA4-31E9-416B-8923-741F9DF555F0Q40818666-3E39A80C-79FB-4DCD-B37B-A89A7C3282A3Q44844167-D06478C3-FFFA-4DB3-B5F1-8C852E67EC51Q51636044-A138B110-4B71-48B5-B644-74FEE7358BB4Q51675882-ACE70C13-E769-45F6-8B36-6FC0D5D77994
P2860
Challenges in multi-plex and mono-plex platforms for the discovery of inflammatory profiles in neurodegenerative diseases.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Challenges in multi-plex and m ...... in neurodegenerative diseases.
@en
Challenges in multi-plex and m ...... in neurodegenerative diseases.
@nl
type
label
Challenges in multi-plex and m ...... in neurodegenerative diseases.
@en
Challenges in multi-plex and m ...... in neurodegenerative diseases.
@nl
prefLabel
Challenges in multi-plex and m ...... in neurodegenerative diseases.
@en
Challenges in multi-plex and m ...... in neurodegenerative diseases.
@nl
P2093
P50
P1433
P1476
Challenges in multi-plex and m ...... in neurodegenerative diseases.
@en
P2093
Arjan Malekzadeh
Heleen Beckerman
Vincent de Groot
P304
P356
10.1016/J.YMETH.2012.03.017
P577
2012-03-24T00:00:00Z